Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2016

Open Access 01-12-2016 | Erratum

Erratum to: Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer

Authors: Deborah Ryan, Steven Carberry, Áine C. Murphy, Andreas U. Lindner, Joanna Fay, Suzanne Hector, Niamh McCawley, Orna Bacon, Caoimhin G. Concannon, Elaine W. Kay, Deborah A. McNamara, Jochen H. M. Prehn

Published in: Journal of Translational Medicine | Issue 1/2016

Login to get access

Excerpt

Unfortunately, the original version of this article [1] contained an error. The title was included incorrectly. The correct can be found here. The title has been corrected in the original article and is also included correctly in this erratum. …
Literature
1.
Ryan D, Carberry S, Murphy ÁC, Linder AU, Fay J, Hector S, McCawley N, Bacon O, Concannon CG, Kay EW, McNamara DA, Prehn JHM. Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. J Transl Med. 2016;14:196. doi:10.​1186/​s12967-016-0948-z.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer
Authors
Deborah Ryan
Steven Carberry
Áine C. Murphy
Andreas U. Lindner
Joanna Fay
Suzanne Hector
Niamh McCawley
Orna Bacon
Caoimhin G. Concannon
Elaine W. Kay
Deborah A. McNamara
Jochen H. M. Prehn
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2016
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-016-0984-8

Other articles of this Issue 1/2016

Journal of Translational Medicine 1/2016 Go to the issue

Research

Increased MACC1 levels in tissues and blood identify colon adenoma patients at high risk

Research

LncRNA MALAT1 promotes development of mantle cell lymphoma by associating with EZH2

Research

Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples

Research

Guizhi-Shaoyao-Zhimu decoction attenuates rheumatoid arthritis partially by reversing inflammation-immune system imbalance

Research

Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling

Review

Early life programming of pain: focus on neuroimmune to endocrine communication
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits